Research programme: small molecule immunotherapeutics for allergy- ALK Abello/Vipergen ApS
Alternative Names: Research programme: allergy immunotherapies- ALK Abello/Vipergen ApS; Research programme: small molecule immunotherapeutics- ALK Abello/Vipergen ApSLatest Information Update: 15 Dec 2021
At a glance
- Originator ALK-Abello; Vipergen ApS
- Class Antiallergics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hypersensitivity